Raymond James announced that it has downgraded Boston Scientific's investment rating from "Strong Buy" to "Outperform," and lowered its target price from $97 to $88.

This rating adjustment reflects analysts' prudent assessment of the company's short-term valuation and growth prospects. Although the rating has been lowered, the "outperform" rating still indicates the institution's optimistic attitude toward Boston Scientific's medium and long-term performance. The adjustment of the target price may be based on a comprehensive consideration of the overall environment of the medical device industry, the company's recent financial performance, and the market competition situation. The market will closely monitor Boston Scientific's performance in upcoming quarters to verify the rationality of this rating adjustment.